HLF and acute lymphoblastic leukemia: Furthermore, all of nine patients with TCF3/HLF-rearranged ALL experienced molecular remission after being treated with blinatumomab, and four of them are in long-term remission after HCT, suggesting that an immunotherapy approach can overcome the chemotherapy resistance [65].